Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000470341 | SCV000548023 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-09-06 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RAD50 protein function. ClinVar contains an entry for this variant (Variation ID: 408380). This missense change has been observed in individual(s) with breast cancer (PMID: 24894818). This variant is present in population databases (rs762562316, gnomAD 0.006%). This sequence change replaces glutamine, which is neutral and polar, with histidine, which is basic and polar, at codon 199 of the RAD50 protein (p.Gln199His). |
Ambry Genetics | RCV000470341 | SCV001186811 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-11-04 | criteria provided, single submitter | clinical testing | The p.Q199H variant (also known as c.597A>C), located in coding exon 5 of the RAD50 gene, results from an A to C substitution at nucleotide position 597. The glutamine at codon 199 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |